Perspective Therapeutics, Inc. (NYSE:CATX) Receives $20.00 Consensus Target Price from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $20.00.

CATX has been the subject of several recent research reports. B. Riley increased their price objective on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 25th. Bank of America initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 price objective on shares of Perspective Therapeutics in a research report on Friday, June 14th. Finally, Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th.

Insider Activity

In other news, Director Lori A. Woods bought 4,587 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was acquired at an average cost of $10.90 per share, for a total transaction of $49,998.30. Following the completion of the purchase, the director now owns 159,985 shares of the company’s stock, valued at $1,743,836.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Jonathan Robert Hunt acquired 2,500 shares of Perspective Therapeutics stock in a transaction on Friday, May 31st. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $35,000.00. Following the purchase, the chief financial officer now directly owns 34,171 shares of the company’s stock, valued at approximately $478,394. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lori A. Woods acquired 4,587 shares of Perspective Therapeutics stock in a transaction on Friday, June 14th. The shares were bought at an average price of $10.90 per share, for a total transaction of $49,998.30. Following the completion of the purchase, the director now directly owns 159,985 shares in the company, valued at $1,743,836.50. The disclosure for this purchase can be found here. Over the last three months, insiders bought 30,814 shares of company stock worth $385,487. 3.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new position in shares of Perspective Therapeutics in the 2nd quarter worth about $630,000. Bank of New York Mellon Corp lifted its position in shares of Perspective Therapeutics by 214.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after buying an additional 93,548 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth about $138,000. Janus Henderson Group PLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth about $15,511,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth about $6,069,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Down 8.3 %

Shares of CATX stock opened at $12.29 on Friday. Perspective Therapeutics has a one year low of $2.05 and a one year high of $19.05. The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $12.15.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The company had revenue of $0.33 million for the quarter. Equities analysts predict that Perspective Therapeutics will post -1.02 earnings per share for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.